

Involvement of the endocannabinoid system in drug addiction

Rafael Maldonado, Olga Valverde and Fernando Berrendero

Laboratori de Neurofarmacologia, Facultat de Ciències de la Salut i de la Vida, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, 08003 Barcelona, Spain

Recent studies have shown that the endocannabinoid system is involved in the common neurobiological mechanism underlying drug addiction. This system participates in the primary rewarding effects of cannabinoids, nicotine, alcohol and opioids, through the release of endocannabinoids in the ventral tegmental area. Endocannabinoids are also involved in the motivation to seek drugs by a dopamine-independent mechanism, demonstrated for psychostimulants and opioids. The endocannabinoid system also participates in the common mechanisms underlying relapse to drug-seeking behaviour by mediating the motivational effects of drug-related environmental stimuli and drug re-exposure. In agreement, clinical trials have suggested that the CB₁ cannabinoid antagonist rimonabant can cause smoking cessation. Thus, CB₁ cannabinoid antagonists could represent a new generation of compounds to treat drug addiction.

Introduction

Drug addiction is a chronic relapsing brain disorder, characterized by neurobiological changes leading to compulsive drug seeking and drug taking despite serious negative consequences, and by loss of control over drug use [1]. Addiction includes complex behavioural and neurobiological processes. All the drugs of abuse produce reinforcing effects that are responsible for the initiation of the addictive disorder. However, other behavioural processes are also crucial for the maintenance of addiction, including the negative consequences of drug abstinence and the different stimuli leading to relapse (e.g. drug-associated cues, stressors and drug re-exposure) [2].

Several groups of compounds that produce different pharmacological effects can lead to addictive behaviour, including opioids, psychostimulants, cannabinoids, alcohol and nicotine. The initial mechanism of action of these drugs implicates different neurochemical targets [3]. However, all these compounds produce neural dysregulations involving similar neurochemical and neuroanatomical pathways [4]. Indeed, multiple studies support the existence of common neurobiological mechanisms for the addictive properties of most drugs of abuse. This information is based on findings showing the crucial role of the mesocorticolimbic dopaminergic pathways, the

endogenous opioid system, and the brain and pituitary stress system in the addictive processes. Drugs of abuse interact with these common brain circuits producing adaptive changes leading to a profound dysregulation of brain motivational and reward pathways [2]. The mesocorticolimbic system represents a common neuronal substrate for the reinforcing properties of drugs of abuse, where both dopamine and opioid transmission are crucial [5]. The major components of this drug reward circuit are the ventral tegmental area (VTA), which contains the dopaminergic cell bodies, and the terminal areas in the basal forebrain [the nucleus accumbens (NAc), olfactory tubercle, amygdala, and frontal and limbic cortices] [6]. These neurochemical circuits are also involved in the negative motivational consequences of drug withdrawal [2]. Mesolimbic dopaminergic neurons receive highly processed information from the cerebral cortex and other areas involved in cognitive functions, and dopamine release in the forebrain has been proposed to serve as a learning signal. Dopamine neurons in the NAc interact with glutamatergic projection neurons from the cerebral cortex, hippocampus and amygdala, providing information about external context and about internal emotional and physiological states. Hence, drug-induced plasticity in these NAc projections contributes to addiction by consolidating reward-driven behaviour [3,7]. Recruitment of brain stress pathways has also been reported as a common change during drug abstinence that seems to be crucial in the reinstatement of drug seeking behaviour [8]. However, the common mechanisms involved in the development of the addictive processes have not been yet completely identified. This review focuses on the recent findings supporting participation of the endocannabinoid system in the common circuitry underlying drug addiction and proposes a mechanistic explanation for this physiopathological role.

Endocannabinoid system and brain reward circuitry

Knowledge of the endocannabinoid system has been largely improved since the cloning in 1990 of the CB₁ cannabinoid receptor, which is activated by Δ^9 -tetrahydrocannabinol (THC), the main psychoactive component of *Cannabis sativa*. This system consists of cannabinoid receptors, endogenous ligands and several proteins responsible for their synthesis and degradation. To date, two subtypes of cannabinoid receptors, CB₁ and CB₂, have been characterized and cloned. CB₁ receptors are the most

Corresponding author: Maldonado, R. (rafael.maldonado@upf.edu).

Available online 17 February 2006

abundant G-protein-coupled receptor in the CNS and are also found in peripheral tissues. CB₂ receptors are mainly located in the cells of the immune system [9], but they have also been recently identified in brainstem, cortex and cerebellum neurons [10]. Several endogenous cannabinoids have been isolated from brain tissue, anandamide and 2-arachidonoylglycerol being the best characterized [9]. Endocannabinoids are thought to act as retrograde messengers in the CNS [11] and behave as neuromodulators in many physiological processes. Accordingly, endocannabinoids released from postsynaptic neurons upon depolarization activate presynaptic CB₁ cannabinoid receptors, resulting in inhibition of the release of both excitatory and inhibitory neurotransmitters. This endocannabinoid retrograde control has also been recently demonstrated after synaptic activation of group I metabotropic glutamate receptors [12] and D₂ dopamine receptors [13].

Several studies support the view that the endocannabinoid system represents a new candidate for the control of drug rewarding properties. Indeed, CB₁ cannabinoid receptors are abundant in the brain reward circuitry and participate in the addictive properties induced by different drugs of abuse. The dopaminergic neurons of the mesocorticolimbic pathway are controlled by excitatory and inhibitory inputs that are modulated by CB₁ cannabinoid receptors. Thus, endocannabinoids can be released following depolarization in the NAc [14] and from dopaminergic neurons in the VTA [13,15], and they modulate glutamatergic and GABAergic afferents by acting as retrograde messengers on CB₁ receptors. The presence of CB₁ receptors in other structures related to motivation and reward, such as the basolateral amygdala and the hippocampus, also contributes to this function of the endocannabinoid system [16]. In addition, endocannabinoids participate in synaptic plasticity in the mesolimbic system. The stimulation of prelimbic cortex afferents

causes long-term depression (LTD) of NAc glutamatergic synapses that is mediated by endocannabinoid release and presynaptic CB₁ receptors [14,17]. Endocannabinoids also produce LTD of inhibitory synaptic transmission in the hippocampus and prepare excitatory synapses for facilitating subsequent induction of long-term potentiation (LTP) [18], which contributes to the plasticity mechanisms reported in the learning processes related to addictive behaviour.

The endocannabinoid system is certainly the primary site of action for the rewarding and pharmacological responses induced by cannabinoids [19,20]. However, this system plays an overall modulatory effect on the reward circuitry and also participates in the rewarding and addictive properties of all prototypical drugs of abuse.

Endocannabinoid system and nicotine addiction

Nicotine addiction is a complex neurochemical process that involves many neurotransmitters, and the endocannabinoid system is crucial in the addictive effects of this drug. Pharmacological studies revealed that non-effective doses of nicotine and THC produced significant conditioned place preference in mice when administered together [21]. Interestingly, the rewarding properties of nicotine, assessed in a place-conditioning paradigm, were absent in knockout mice lacking CB₁ receptors [22] (Table 1). By contrast, CB₁ knockout mice learned to self-administer nicotine using an acute paradigm in mice that were restrained to avoid their movement [23]. However, this acute paradigm fails to evaluate the maintenance of a stable operant self-administration response, and nicotine effects on anxiety-like behaviour could influence this self-administration response in restrained animals [23]. Pharmacological studies using the selective CB₁ receptor antagonist rimonabant (Box 1) have confirmed the involvement of these receptors in nicotine addiction (Table 2). Thus, rimonabant reduces

Table 1. Changes to the addictive properties of drugs observed in CB₁ cannabinoid receptor knockout mice

Drug	Model	Effect	Refs
Morphine	Conditioned place preference	Suppression	[45]
		No change	[46]
	Behavioural sensitization	Suppression	[45]
	Self-administration in restrained mice	Suppression	[19]
		Suppression	[23]
Withdrawal syndrome	Attenuation	[19]	
Ethanol	Conditioned place preference	Attenuation	[79]
		Attenuation	[40]
	Two-bottle choice (voluntary consumption)	Attenuation	[37]
		No change	[41]
		Attenuation	[38]
	Withdrawal syndrome	Attenuation	[34]
		Suppression	[41]
Nicotine	Extracellular dopamine levels (<i>in vivo</i> microdialysis)	Increase	[38]
		Suppression	[37]
	Conditioned place preference	Suppression	[22]
		No change	[23]
		No change	[22]
Cocaine	Conditioned place preference	No change	[45]
		No change	[40]
	Behavioural sensitization	No change	[45]
		No change	[23]
		Attenuation	[63]
Amphetamine	Self-administration in restrained mice	No change	[63]
		No change	[23]

Box 1. Chemical names

AM-251: *N*-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide

HU-210: (6*aR*)-*trans*-3-(1,1-dimethylheptyl)-6*a*, 7, 10, 10*a*-tetrahydro-1-hydroxy-6,6-dimethyl-6*H*-dibenzo[*b,d*]pyran-9-methanol

Rimonabant: *N*-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide

WIN 55,212-2: (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo[1,2,3-*de*]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate

nicotine operant self-administration [24] and nicotine-induced conditioned place preference in rats [25], although no effect was observed when nicotine place preference was evaluated 3 or 12 weeks after the initial conditioning phase [26]. Nicotine relapse induced by associated environmental stimuli is also mediated by activation of the endocannabinoid system. Thus, rimonabant attenuated the influence of these environmental stimuli on nicotine-seeking behaviour in rats [27,28]. CB₁ receptors do not seem to participate in the development of nicotine physical dependence because rimonabant did not precipitate a withdrawal syndrome in nicotine-dependent mice [29] and the severity of nicotine abstinence was not modified in CB₁ knockout mice [22]. The effects of the endocannabinoid system on the rewarding properties of nicotine are related to modulation of the extent to which nicotine activates the mesolimbic dopaminergic pathway. Thus, *in vivo* microdialysis studies revealed that rimonabant pre-treatment blocks nicotine-enhanced extracellular dopamine levels in the shell of the NAc and in the bed nucleus of the stria terminalis [24]. In agreement with these behavioural and biochemical results in rodents, Phase III clinical trials have revealed that rimonabant is significantly effective in obtaining smoking cessation

[Studies with Rimonabant and Tobacco Use in North America (STRATUS-North America)] and can produce a strong tendency for such cessation in a population with a more intense daily tobacco consumption (STRATUS-Europe) [30]. These results suggest that CB₁ cannabinoid receptors represent a promising target for new therapies to treat tobacco addiction.

Endocannabinoid system and alcohol addiction

Cannabinoids and alcohol activate similar reward pathways, and CB₁ receptors also seem to regulate the reinforcing properties of alcohol. Thus, the acute administration of cannabinoid agonists stimulates voluntary alcohol intake in Sardinian alcohol-preferring (sP) and Wistar rats [31,32]. In agreement, blockade of CB₁ receptors reduces alcohol consumption in C57BL/6 mice, and in Wistar and sP rats [33–35] (Table 2). However, part of this effect can be attributed to a more general suppression of food and fluid intake [36]. Genetic inactivation of CB₁ receptors has confirmed these pharmacological data (Table 1). Thus, a decrease of voluntary alcohol intake in CB₁ knockout mice has been shown using a two-bottle free-choice paradigm [34,37–39], and ethanol-induced place preference was reduced in these mutants [39,40]. A role of CB₁ receptors in stress-induced alcohol drinking and ethanol withdrawal has also been reported using knockout mice [41], although the same study showed normal ethanol drinking behaviour under non-stressful conditions in these animals. CB₁ receptors are also involved in the mechanisms mediating alcohol relapse. Accordingly, the exposure to the cannabinoid agonists WIN 55 212-2 (Box 1) or THC promotes the relapse of alcohol use in abstinent rats [42,43], and rimonabant reduces conditioned reinstatement of

Table 2. Effects of rimonabant on drug addictive properties

Drug	Model	Dose (mg kg ⁻¹) ^a	Effect	Animal	Refs
Morphine	Conditioned place preference	0.1 (ip)	Attenuation	Rat	[80]
		3.0 (ip)	Suppression	Rat	[47]
Heroin	Self-administration	0.25 (ip)	Suppression	Rat	[47]
	Self-administration	3.0 (ip)	Suppression	Rat	[47]
		3.0 (ip)	Suppression	Rat	[81]
	Self-administration (relapse)	0.3–3.0 (ip)	Attenuation	Rat	[82]
		1.0 and 3.0 (ip)	Attenuation	Rat	[48]
		0.3 (ip)	Suppression	Rat	[50]
		1.0 and 3.0 (ip)	Attenuation	Rat	[48]
	Extracellular dopamine levels (<i>in vivo</i> microdialysis)	0.3–3.0 (ip)	No change	Rat	[82]
1.0 (sc)		No change	Rat	[53]	
Ethanol	Two-bottle choice (voluntary consumption)	0.3–3.0 (sc)	Attenuation	Rat, mouse	[33]
		2.5–10.0 (ip)	Attenuation	Rat	[83]
		0.3–3.0 (ip)	Attenuation	Rat	[84]
		3.0 (ip)	Attenuation	Mouse	[34]
	Self-administration	0.3–3.0 (ip)	Attenuation	Rat	[35]
	Self-administration (relapse)	1.0 and 3.0 (ip)	Attenuation	Rat	[35]
	Extracellular dopamine levels (<i>in vivo</i> microdialysis)	3.0 (ip)	Attenuation	Rat	[24]
		3.0 (ip)	Suppression	Mouse	[37]
Nicotine	Conditioned place preference	1.0 and 3.0 (ip)	Suppression	Rat	[25]
	Self-administration	0.3 and 1.0 (ip)	Attenuation	Rat	[24]
	Self-administration (relapse)	1.0 and 3.0 (ip)	Attenuation	Rat	[28]
		1.0 (ip)	Attenuation	Rat	[27]
	Extracellular dopamine levels (<i>in vivo</i> microdialysis)	1.0 and 3.0 (ip)	Attenuation	Rat	[24]
Cocaine	Self-administration in restrained mice	1.0 (ip)	No change	Mouse	[85]
	Self-administration	1.0–3.0 (ip)	Attenuation	Mouse	[63]
	Self-administration (relapse)	0.3–3.0 (sc)	Attenuation	Rat	[64]

^aAbbreviations: ip, intraperitoneal; sc, subcutaneous.

ethanol-seeking behaviour in rats [35]. The endocannabinoid system seems to participate in alcohol rewarding properties by modulating its effects on the activation of mesolimbic dopamine transmission. *In vivo* microdialysis studies revealed that alcohol did not enhance extracellular levels of dopamine in the NAc in CB₁ knockout mice [37]. A similar result was obtained when wild-type mice were pre-treated with rimonabant before alcohol administration [37]. Clinical data on the possible efficacy of CB₁ receptor antagonists in the treatment of alcohol addiction are not still available.

Endocannabinoid system and opioid addiction

Several studies have revealed the existence of functional bidirectional interactions between cannabinoid and opioid systems, and both systems participate in the common circuits involved in the addictive properties of different drugs of abuse [44]. CB₁ cannabinoid receptors have an important role in the rewarding properties of opioids. Thus, morphine-induced conditioned place preference [45] and intravenous self-administration [19] were abolished in knockout mice lacking CB₁ receptors, although contradictory results have been reported on the place-conditioning paradigm [46] (Table 1). In agreement, rimonabant reduced opioid self-administration and conditioned place preference in rodents [47,48] (Table 2). The effects of rimonabant on heroin self-administration were more pronounced when the effort required to obtain a heroin infusion was enhanced. Indeed, rimonabant markedly impaired heroin self-administration under a progressive ratio (PR) schedule of reinforcement, whereas this effect was attenuated under a fixed ratio (FR) schedule of 5 and almost disappeared at a FR1 [49] (Box 2). Rimonabant also prevented heroin-seeking behaviour after a long period of extinction, and the cannabinoid agonist HU-210 (Box 1) reinstated such a seeking behaviour [48–50]. Reciprocally, the rewarding effects induced by THC were suppressed in μ -opioid receptor knockout mice [51], and were attenuated by the opioid receptor antagonist naltrexone in monkeys [52]. Both opioid and cannabinoid rewarding responses are related to their facilitatory effects on mesolimbic dopamine transmission [5]. Rimonabant did not prevent the activation of dopamine transmission induced by heroin, although the opioid receptor antagonist naloxone prevented such a biochemical effect from being produced by cannabinoids [53,54].

Cross-dependence has also been reported between opioid and cannabinoid compounds. Thus, naloxone induced a withdrawal syndrome in THC-dependent rats,

whereas rimonabant precipitated abstinence in morphine-dependent animals [55,56]. In agreement, a robust attenuation in the severity of naloxone-precipitated morphine withdrawal was reported in CB₁ knockout mice [19]. Reciprocally, the expression of cannabinoid withdrawal was decreased in knockout mice lacking the gene encoding pre-proenkephalin and in double knockout mice deficient in μ and δ opioid receptors [54]. Both opioid and cannabinoid withdrawal syndromes have been associated with compensatory changes in the cAMP pathway. Thus, enhanced activity of several components of the cAMP pathways has been reported during opioid and cannabinoid abstinence, although different brain structures are involved in these compensatory mechanisms [4,54]. Changes in the cAMP pathway occur mainly in the locus coeruleus and some limbic structures, such as the NAc, during opioid withdrawal, whereas these alterations were selectively located in the cerebellum in the case of cannabinoid withdrawal [4,54]. Changes to the mitogen-activated protein (MAP) kinases cascade seem to be another common compensatory modification during the development of opioid and cannabinoid physical dependence [57]. Therefore, the endocannabinoid system is crucial not only in opioid-induced rewarding effects, but also in development of physical dependence during chronic opioid administration. The existence of bidirectional interactions between the endogenous cannabinoid and opioid systems provides neurobiological support for this role of the endocannabinoid system.

Endocannabinoid system and psychostimulant addiction

The mechanism of action of psychostimulants differs from that of other drugs of abuse in that they affect the mesolimbic dopaminergic terminals directly. Indeed, psychostimulants enhance activity of dopaminergic neurons by directly acting on the reuptake of monoamines, binding to one or multiple monoamine transporters [58]. This mechanism is important for understanding the particular involvement of the endocannabinoid system in psychostimulant rewarding effects. Several behavioural responses induced by acute and chronic administration of psychostimulants were not modified in CB₁ knockout mice (Table 1). Interestingly, cocaine-induced conditioned place preference and locomotor behavioural sensitization were not modified in these mice [45]. These knockout mice also learned to self-administer cocaine and amphetamine when using an acute paradigm in restrained animals [23], and rimonabant did not interfere with cocaine self-administration in rats [48] or monkeys [59] trained under FR schedules of reinforcement (Table 2). These results indicate that CB₁ receptors are not involved in the primary reinforcing effects of psychostimulants. By contrast, rimonabant decreased the acquisition but not the expression of conditioned place preference to cocaine [60], whereas the CB₁ antagonist AM-251 (Box 1) decreased methamphetamine self-administration under a FR schedule in rats [61]. In addition, THC and cannabidiol facilitated the extinction of place preference induced by cocaine and amphetamine, although this effect was not reversed by rimonabant [62]. A recent study using

Box 2. Technical terms

Breaking points: the maximal numbers of operant responses that the animal achieves in order to obtain an injection of the drug.

Fixed ratio (FR) schedule: a FR schedule of drug self-administration requires a fixed number of operant responses to obtain a drug injection. Such schedules are used mainly to evaluate the acquisition and maintenance of drug self-administration.

Progressive ratio (PR) schedule: in a PR schedule of drug self-administration, the response requirement to earn a drug injection escalates progressively during the session. This provides information about the reinforcing strength of the drug.




Figure 1. Suppression of CB₁ cannabinoid receptors impairs cocaine self-administration, but does not modify the effects of cocaine on extracellular dopamine levels in the nucleus accumbens (NAc). **(a)** CB₁ knockout (KO) and wild-type (WT) littermates self-administered cocaine (1 mg kg⁻¹ per infusion) under a fixed ratio 1 schedule of reinforcement. Bars represent the average of the number of nose pokes into the active and inactive holes required to meet criteria for acquisition of the cocaine self-administration behaviour during three consecutive sessions. **(b)** Effects of rimonabant (0.3, 1.0 and 3.0 mg kg⁻¹, intraperitoneal administration) and genetic disruption of CB₁ receptors on the breaking points achieved under a progressive ratio schedule of reinforcement (Box 2). **(c)** Acute cocaine administration (20 mg kg⁻¹, intraperitoneal administration) enhanced extracellular dopamine levels in the NAc similarly in wild-type and CB₁ knockout mice. Effects on dopamine dialysate were determined by *in vivo* microdialysis from the NAc of wild-type and CB₁ knockout mice. The arrow indicates cocaine or saline administration at time 0. Values are expressed as mean ± SEM. One star indicates *P* < 0.05; two stars indicate *P* < 0.01. Adapted, with permission, from [63].

CB₁ knockout mice has provided new insights on these mechanisms [63]. Indeed, the acquisition of an operant response to self-administer cocaine was impaired in these mutants mainly when the effort required to obtain a cocaine infusion was enhanced. Thus, the breaking point achieved on a PR schedule of reinforcement was significantly reduced in CB₁ knockout mice, whereas self-administration behaviour was only slightly attenuated on a FR1 schedule (Figure 1). A similar result was obtained on the PR schedule after the blockade of these receptors using rimonabant in wild-type mice [63] (Figure 1). This impairment in cocaine self-administration indicates a decreased motivation for maintaining cocaine-seeking behaviour, providing a role for CB₁ receptors in consolidation of the psychostimulant addictive process. Furthermore, CB₁ receptors are also required to reinstate cocaine self-administration. Thus, the cannabinoid agonist HU-210 induced relapse to cocaine seeking after a prolonged withdrawal period, whereas rimonabant attenuated relapse induced by environmental cocaine-associated cues or cocaine re-exposure [64,65].

The precise mechanisms underlying the modulatory role of the endocannabinoid system on psychostimulant rewarding effects remain to be elucidated. These mechanisms seem to be independent from the activating effects on mesolimbic dopamine-mediated transmission. Thus, the enhancement of extracellular dopamine levels produced by cocaine in the NAc was not modified in CB₁ knockout mice [63] (Figure 1). Activation of the mesolimbic circuitry is essential for psychostimulants to induce feelings of reward, and CB₁ receptors are then not required to obtain the primary reinforcing effects of cocaine. Participation of CB₁ receptors in the motivation to maintain cocaine self-administration should therefore involve other neurochemical systems related to this complex addictive behaviour. Thus, amphetamine releases endocannabinoids in the amygdala to produce LTD by a dopamine-independent mechanism mediated by CB₁ receptors [66],

and these endocannabinoids participate in the synaptic plasticity produced by psychostimulants in mesocortico-limbic structures [67]. Hence, although the endocannabinoid system does not participate in the primary reinforcing effects of psychostimulants, it is important for maintaining psychostimulant seeking behaviour, probably by modulating synaptic processes induced by these drugs.

Mechanisms involved in modulation of the rewarding circuitry by endocannabinoids

CB₁ cannabinoid receptors are present in the different regions of the brain reward circuitry, including the VTA and the NAc, and also in several areas projecting to these two structures, such as the prefrontal cortex, central amygdala and hippocampus [68]. Acting as a retrograde messenger, endocannabinoids modulate the glutamatergic excitatory and GABAergic inhibitory synaptic inputs into the VTA and the glutamate transmission in the NAc (Figure 2). Thus, the activation of CB₁ receptors present on axon terminals of GABAergic neurons in the VTA would inhibit GABA transmission, removing this inhibitory input on dopaminergic neurons [15,69]. Glutamate synaptic transmission from neurons of the prefrontal cortex in the VTA and NAc is similarly modulated by the activation of CB₁ receptors [13,70]. The final effect on the modulation of VTA dopaminergic activity by endocannabinoids would depend on the functional balance between these inhibitory GABAergic and excitatory glutamatergic inputs, which are both inhibited by endocannabinoids under different physiological conditions.

The modulatory role of the endocannabinoid system on the primary rewarding effects of drugs of abuse might depend on endocannabinoid release in the VTA [69]. Thus, the endocannabinoid system seems to be involved in the primary rewarding effects of cannabinoids, opioids, nicotine and alcohol because these drugs increase dopaminergic neuron firing rates, thus making




Figure 2. Possible sites of endocannabinoid action in modulation of drug rewarding effects. In the ventral tegmental area (VTA), CB₁ cannabinoid receptors are located on presynaptic glutamatergic and GABAergic neurons. By contrast, VTA dopaminergic neurons do not synthesize CB₁ cannabinoid receptors. Activation of CB₁ receptors in the VTA by endocannabinoids (EC; broken red arrows) produces inhibition of GABA release, thus removing the inhibitory effect of these GABAergic cells on dopaminergic neurons. In addition, the increase of dopaminergic neuron activity induces release from the dopaminergic cells of endocannabinoids that, acting in a retrograde manner on presynaptic CB₁ receptors, inhibit both inhibitory GABAergic and excitatory glutamatergic inputs to VTA dopaminergic neurons. Glutamatergic projections from the basolateral amygdala (BLA) and hippocampus (HIP), which are involved in motivation and memory processes related to drug rewarding effects, are also under the control of CB₁ receptors, through an inhibitory effect on presynaptic inhibitory neurons that release both GABA and cholecystokinin (CCK). In the nucleus accumbens (NAc), endocannabinoids behave as retrograde modulators acting mainly on CB₁ receptors on the axon terminals of glutamatergic neurons. The subsequent inhibition of glutamate release inhibits the GABAergic neurons that originate in the NAc and project to the VTA, thus indirectly activating VTA dopaminergic neurons. Endocannabinoids have also been demonstrated to participate in synaptic plasticity in the NAc. Thus, repetitive activation of prelimbic glutamatergic afferents to the NAc results in long-term depression (LTD) of this excitatory transmission that depends on endocannabinoids and CB₁ receptors [14]. Chronic [77] or even a single [78] THC exposure modifies this form of synaptic plasticity, which is important for the development of the addictive process. Endocannabinoid release in the VTA participates in the modulation of drug rewarding effects [69], which would explain the involvement of CB₁ receptors in the rewarding properties of opiates, ethanol, THC and nicotine. Hence, CB₁ receptors would not participate in the primary rewarding effects of psychostimulants because they essentially act on dopaminergic axon terminals in the NAc. Nevertheless, somatodendritic dopamine release induced by psychostimulants in the VTA could promote endocannabinoid release in this brain area [13]. Finally, CB₁ receptors on the glutamatergic projections from the prefrontal cortex (PFC) would be important to modulate motivation to seek the drug.

possible the release of endocannabinoids in the VTA. However, psychostimulants enhance dopamine levels in the NAc by directly acting on dopaminergic axon terminals. This mechanism of action avoids endocannabinoid release in the VTA and could explain the lack of alteration of primary psychostimulant rewarding effects in the absence of CB₁ receptors [69,71]. In addition, although chronic treatment with THC, nicotine or alcohol increases endocannabinoid content in the limbic forebrain, chronic cocaine reduces 2-arachidonoylglycerol content in these brain structures, indicating that psychostimulants and other drugs of abuse regulate endocannabinoid transmission differently [72]. Similarly, chronic administration of cocaine, but not ethanol or

nicotine, decreases mRNA levels for CB₁ receptors in several brain structures [73].

The endocannabinoid system also modulates the motivation to seek psychostimulants and opioids by a mechanism independent from release of dopamine in the NAc. CB₁ receptors are present in the prefrontal cortex, which constitutes a nexus for sensory integration, emotional processing and hedonic experience. This brain area is an important component in the addictive phenomenon because it processes the reward to become a 'hedonic experience' [74]. Hence, endocannabinoids could be involved in the motivation to obtain the drug by linking the reward to a 'hedonic experience' in the prefrontal cortex.

The mechanisms underlying the role of the endocannabinoid system in relapse to drug-seeking behaviour produced by drug-related environmental stimuli and drug re-exposure seem related to modulation of the impact of reward-related memories. Indeed, endocannabinoids acting as retrograde messengers mediate LTP and/or LTD of synaptic transmission in several addiction and memory-related brain areas, including the NAc, prefrontal cortex, amygdala and hippocampus [65]. These effects of endocannabinoids on synaptic plasticity might consolidate the reward-driven behaviour required to establish the addictive processes.

The recent identification of CB₂ receptors in the brain presents an alternative site of action for endocannabinoids [10]. These CB₂ receptors are functionally active because their stimulation, together with CB₁ receptor activation, inhibits morphine-6-glucuronide-induced vomiting at a central level. Therefore, CB₂ receptors are potentially involved in other CNS-mediated effects of cannabinoids that have previously been attributed to CB₁ receptors. Further studies are required to understand the precise role of central CB₂ receptors, and the possible alteration of their physiological activity during drug addictive processes. The possible involvement of other neurochemical circuits in the effects of the endocannabinoid system on reward function cannot be excluded. Thus, endocannabinoids facilitate the effects of orexin-releasing neurons in the hypothalamus, which also project to the NAc and the VTA. Interestingly, hypothalamic orexins, in addition to endocannabinoids, are directly involved in the rewarding effects of drugs of abuse and the relapse to drug-seeking behaviour [75].

Therefore, the endocannabinoid system represents a key component in the common neurobiological substrate of drug addiction, and the CB₁ receptor is a possible candidate to explain genomic variations that might determine human addiction vulnerability [76].

Concluding remarks

The endocannabinoid system participates in the addictive properties of all prototypical drugs of abuse by at least three complementary mechanisms. First, the system is directly involved in the primary rewarding effects of cannabinoids, nicotine, alcohol and opioids by acting on common cellular mechanisms and/or by permitting the effects of these drugs on mesolimbic transmission. Second, the endocannabinoid system is involved in the motivation

to seek the drug by a dopamine-independent mechanism; this has been demonstrated for psychostimulants and opioids and might also be the case for other drugs of abuse. Third, this system is implicated in relapse to drug-seeking behaviour participating in the motivational effects of drug-related environmental stimuli and drug re-exposure, probably by acting on the synaptic plasticity underlying memory processes. Further studies will be required to clarify the precise mechanisms involved in this physiological role of the endocannabinoid system, which has promising clinical consequences. Indeed, CB₁ cannabinoid antagonists might represent a new generation of compounds to treat a wide range of drug addictive processes, as clinical trials have already indicated for smoking cessation. Pharmaceutical companies have now focused the target of these new compounds in the treatment of tobacco dependence and other diseases such as obesity and cardiovascular risk. The possible application of CB₁ antagonists to other addictive processes remains to be demonstrated. Finally, the recent identification of CB₂ receptors in the brain has suggested that they might be a new therapeutic target for treatment of CNS disorders, and possible involvement of these receptors in drug addiction remains open.

Acknowledgements

Preparation of this manuscript has been supported by grants from National Institutes of Health (1R01-DA016768-0111), Ministerio de Educación y Ciencia (SAF2004-0568, BFU2004-00920/BFI and GEN2003-20651-C06-04), Instituto de Salud Carlos III (04/1485, C03/06 and G03/005), Generalitat de Catalunya (2002 SGR00193), and the European Commission (VI Programa Marco IP OJ 2004/C164, N°005166, GENADDICT and OJ 2002/C315/01, N° 503474, NEWMOOD). F.B. is a researcher supported by the Programa Ramón y Cajal (Ministerio de Educación y Ciencia).

References

- Camí, J. and Farré, M. (2003) Drug addiction. *N. Engl. J. Med.* 349, 975–986
- Koob, G.F. *et al.* (2004) Neurobiological mechanisms in the transition from drug use to drug dependence. *Neurosci. Biobehav. Rev.* 27, 739–749
- Hyman, S.E. and Malenka, R.C. (2001) Addiction and the brain: the neurobiology of compulsion and its persistence. *Nat. Rev. Neurosci.* 2, 695–703
- Nestler, E.J. (2004) Molecular mechanisms of drug addiction. *Neuropharmacology* 47, 24–32
- Maldonado, R. (2003) Opioid system involvement in cannabinoid tolerance and dependence. In *Molecular Biology of Drug Addiction* (Maldonado, R., ed.), pp. 221–248, Humana Press
- Wise, R.A. (2004) Dopamine, learning and motivation. *Nat. Rev. Neurosci.* 5, 483–494
- Kauer, J.A. (2004) Learning mechanisms in addiction synaptic plasticity in the ventral tegmental area as a result of exposure to drugs of abuse. *Annu. Rev. Physiol.* 66, 447–475
- Piazza, P.V. and Le Moal, M. (1998) The role of stress in drug self-administration. *Trends Pharmacol. Sci.* 19, 67–74
- Fride, E. and Mechoulam, R. (2003) New advances in the identification and physiological role of the different components of the endogenous cannabinoid system. In *Molecular Biology of Drug Addiction* (Maldonado, R., ed.), pp. 173–198, Humana Press
- Van Sickle, M.D. *et al.* (2005) Identification and functional characterization of brainstem cannabinoid CB₂ receptors. *Science* 310, 329–332
- Wilson, R.I. and Nicoll, R.A. (2002) Endocannabinoid signaling in the brain. *Science* 296, 678–682
- Jung, K.M. *et al.* (2005) Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. *Mol. Pharmacol.* 68, 1196–1202
- Melis, M. *et al.* (2004) Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB₁ receptors. *J. Neurosci.* 24, 53–62
- Robbe, D. *et al.* (2002) Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. *Proc. Natl. Acad. Sci. U. S. A.* 99, 8384–8388
- Riegel, A.C. and Lupica, C.R. (2004) Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. *J. Neurosci.* 24, 11070–11078
- Katona, I. *et al.* (2001) Distribution of CB₁ cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. *J. Neurosci.* 21, 9506–9518
- Gerdeman, G.L. *et al.* (2002) Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. *Nat. Neurosci.* 5, 446–451
- Chevalere, V. and Castillo, P.E. (2004) Endocannabinoid-mediated metaplasticity in the hippocampus. *Neuron* 43, 871–881
- Ledent, C. *et al.* (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB₁ receptor knockout mice. *Science* 283, 401–404
- Lichtman, A.H. and Martin, B.R. (2005) Cannabinoid tolerance and dependence. In *Cannabinoids* (Pertwee, R., ed.), pp. 691–717, Springer-Verlag
- Valjent, E. *et al.* (2002) Behavioural and biochemical evidence for interactions between Δ^9 -tetrahydrocannabinol and nicotine. *Br. J. Pharmacol.* 135, 564–578
- Castañé, A. *et al.* (2002) Lack of CB₁ cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. *Neuropharmacology* 43, 857–867
- Cossu, G. *et al.* (2001) Cannabinoid CB₁ receptor knockout mice fail to self-administer morphine but not other drugs of abuse. *Behav. Brain Res.* 118, 61–65
- Cohen, C. *et al.* (2002) SR141716, a central cannabinoid (CB₁) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. *Behav. Pharmacol.* 13, 451–463
- Le Foll, B. and Goldberg, S.R. (2004) Rimonabant, a CB₁ antagonist, blocks nicotine-conditioned place preferences. *NeuroReport* 15, 2139–2143
- Forget, B. *et al.* (2005) Cannabinoid CB₁ receptors are involved in motivational effects of nicotine in rats. *Psychopharmacology (Berl.)* 181, 722–734
- Cohen, C. *et al.* (2005) Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB₁) receptor antagonist, rimonabant (SR141716). *Neuropsychopharmacology* 30, 145–155
- De Vries, T.J. *et al.* (2005) Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A. *Behav. Brain Res.* 161, 164–168
- Balerio, G.N. *et al.* (2004) Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. *Eur. J. Neurosci.* 20, 2737–2748
- Fernandez, J.R. and Allison, D.B. (2004) Rimonabant Sanofi-Synthelabo. *Curr. Opin. Investig. Drugs* 5, 430–435
- Gallate, J.E. *et al.* (1999) Increased motivation for beer in rats following administration of a cannabinoid CB₁ receptor agonist. *Eur. J. Pharmacol.* 370, 233–240
- Colombo, G. *et al.* (2002) Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats. *Psychopharmacology (Berl.)* 159, 181–187
- Arnone, M. *et al.* (1997) Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB₁) receptors. *Psychopharmacology (Berl.)* 132, 104–106
- Wang, L. *et al.* (2003) Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. *Proc. Natl. Acad. Sci. U. S. A.* 100, 1393–1398
- Cippitelli, A. *et al.* (2005) Cannabinoid CB₁ receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. *Eur. J. Neurosci.* 21, 2243–2251
- McGregor, I.S. and Gallate, J.E. (2004) Rats on the grog: novel pharmacotherapies for alcohol craving. *Addict. Behav.* 29, 1341–1357

- 37 Hungund, B.L. *et al.* (2003) Cannabinoid CB₁ receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. *J. Neurochem.* 84, 698–704
- 38 Naassila, M. *et al.* (2004) Decreased alcohol self-administration and increased alcohol sensitivity and withdrawal in CB₁ receptor knockout mice. *Neuropharmacology* 46, 243–253
- 39 Thanos, P.K. *et al.* (2005) Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB₁ receptors. *Behav. Brain Res.* 164, 206–213
- 40 Houchi, H. *et al.* (2005) CB₁ receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D₂ receptors. *Neuropsychopharmacology* 30, 339–349
- 41 Racz, I. *et al.* (2003) A critical role for the cannabinoid CB₁ receptors in alcohol dependence and stress-stimulated ethanol drinking. *J. Neurosci.* 23, 2453–2458
- 42 López-Moreno, J.A. *et al.* (2004) Long-lasting increase of alcohol relapse by the cannabinoid receptor agonist WIN 55,212-2 during alcohol deprivation. *J. Neurosci.* 24, 8245–8252
- 43 McGregor, I.S. *et al.* (2005) Delta⁹-THC reinstates beer- and sucrose-seeking behaviour in abstinent rats: comparison with midazolam, food deprivation and predator odour. *Alcohol Alcohol.* 40, 35–45
- 44 Maldonado, R. and Rodriguez de Fonseca, F. (2002) Cannabinoid addiction: behavioral models and neural correlates. *J. Neurosci.* 22, 3326–3331
- 45 Martin, M. *et al.* (2000) Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB₁ knockout mice. *Eur. J. Neurosci.* 12, 4038–4046
- 46 Rice, O.V. *et al.* (2002) Conditioned place preference to morphine in cannabinoid CB₁ receptor knockout mice. *Brain Res.* 945, 135–138
- 47 Navarro, M. *et al.* (2001) Functional interaction between opioid and cannabinoid receptors in drug self-administration. *J. Neurosci.* 21, 5344–5350
- 48 De Vries, T.J. *et al.* (2003) Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. *Psychopharmacology (Berl.)* 168, 164–169
- 49 Solinas, M. *et al.* (2003) The cannabinoid CB₁ antagonist N-piperidyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. *J. Pharmacol. Exp. Ther.* 306, 93–102
- 50 Fattore, L. *et al.* (2003) Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. *Eur. J. Neurosci.* 17, 1723–1726
- 51 Ghozland, S. *et al.* (2002) Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. *J. Neurosci.* 22, 1146–1154
- 52 Justinova, Z. *et al.* (2003) The opioid antagonist naltrexone reduces the reinforcing effects of Δ⁹ tetrahydrocannabinol (THC) in squirrel monkeys. *Psychopharmacology (Berl.)* 173, 186–194
- 53 Tanda, G. *et al.* (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. *Science* 276, 2048–2050
- 54 Valverde, O. *et al.* (2004) Involvement of endogenous opioid system in cannabinoid responses. *Curr. Med. Chem.* 4, 183–193
- 55 Navarro, M. *et al.* (1998) CB₁ cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. *NeuroReport* 9, 3397–3402
- 56 Maldonado, R. (2002) Study of cannabinoid dependence in animals. *Pharmacol. Ther.* 95, 153–164
- 57 Rubino, T. *et al.* (2005) Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects. *J. Neurochem.* 93, 984–991
- 58 Rothman, R.B. and Baumann, M.H. (2003) Monoamine transporters and psychostimulant drugs. *Eur. J. Pharmacol.* 479, 23–40
- 59 Tanda, G. *et al.* (2000) Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. *Nat. Neurosci.* 3, 1073–1074
- 60 Chaperon, F. *et al.* (1998) Involvement of central cannabinoid (CB₁) receptors in the establishment of place conditioning in rats. *Psychopharmacology (Berl.)* 135, 324–332
- 61 Vinklerova, J. *et al.* (2002) Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251. *J. Psychopharmacol.* 16, 139–143
- 62 Parker, L.A. *et al.* (2004) Effect of low doses of Δ⁹-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. *Psychopharmacology (Berl.)* 175, 360–366
- 63 Soria, G. *et al.* (2005) Lack of CB₁ cannabinoid receptor impairs cocaine self-administration. *Neuropsychopharmacology* 30, 1670–1680
- 64 De Vries, T.J. *et al.* (2001) A cannabinoid mechanism in relapse to cocaine seeking. *Nat. Med.* 7, 1151–1154
- 65 De Vries, T.J. and Schoffelmeier, A.N. (2005) Cannabinoid CB₁ receptors control conditioned drug seeking. *Trends Pharmacol. Sci.* 26, 420–426
- 66 Huang, Y.C. *et al.* (2003) Mediation of amphetamine-induced long-term depression of synaptic transmission by CB₁ cannabinoid receptors in the rat amygdala. *J. Neurosci.* 23, 10311–10320
- 67 Wolf, M.E. *et al.* (2004) Psychomotor stimulants and neuronal plasticity. *Neuropharmacology* 47(Suppl. 1), 61–79
- 68 Gardner, E.L. (2005) Endocannabinoid signaling system and brain reward: emphasis on dopamine. *Pharmacol. Biochem. Behav.* 81, 263–284
- 69 Lupica, C.R. and Riegel, A.C. (2005) Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. *Neuropharmacology* 48, 1105–1116
- 70 Robbe, D. *et al.* (2001) Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. *J. Neurosci.* 21, 109–116
- 71 Le Foll, B. and Goldberg, S.R. (2005) Cannabinoid CB₁ receptor antagonists as promising new medications for drug dependence. *J. Pharmacol. Exp. Ther.* 312, 875–883
- 72 González, S. *et al.* (2002) Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. *Brain Res.* 954, 73–81
- 73 González, S. *et al.* (2002) Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB₁ receptor binding and mRNA levels. *Drug Alcohol Depend.* 66, 77–84
- 74 Kringelbach, M.L. (2005) The human orbitofrontal cortex: linking reward to hedonic experience. *Nat. Rev. Neurosci.* 6, 691–702
- 75 Harris, G.C. *et al.* (2005) A role for lateral hypothalamic orexin neurons in reward seeking. *Nature* 437, 556–559
- 76 Zhang, P.W. *et al.* (2004) Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. *Mol. Psychiatry* 9, 916–931
- 77 Hoffman, A.F. *et al.* (2003) Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure. *J. Neurosci.* 23, 4815–4820
- 78 Mato, S. *et al.* (2004) A single *in-vivo* exposure to Δ⁹THC blocks endocannabinoid-mediated synaptic plasticity. *Nat. Neurosci.* 7, 585–586
- 79 Lichtman, A.H. *et al.* (2001) Opioid and cannabinoid modulation of precipitated withdrawal in Δ⁹-tetrahydrocannabinol and morphine-dependent mice. *J. Pharmacol. Exp. Ther.* 298, 1007–1014
- 80 Singh, M.E. *et al.* (2004) A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine. *Brain Res.* 1026, 244–253
- 81 Navarro, M. *et al.* (2004) Cannabinoid receptor antagonist reduces heroin self-administration only in dependent rats. *Eur. J. Pharmacol.* 501, 235–237
- 82 Caille, S. and Parsons, L.H. (2003) SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats. *Eur. J. Neurosci.* 18, 3145–3149
- 83 Colombo, G. *et al.* (1998) Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716. *Alcohol Alcohol.* 33, 126–130
- 84 Freedland, C.S. *et al.* (2001) Effects of SR141716A on ethanol and sucrose self-administration. *Alcohol. Clin. Exp. Res.* 25, 277–282
- 85 Lesscher, H.M. *et al.* (2005) Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization. *Eur. Neuropsychopharmacol.* 15, 31–37